1480P Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
- Resource Type
- Source
- Annals of Oncology. 32:S1092-S1093
- Subject
Oncology medicine.medical_specialty Pancreatic ductal adenocarcinoma business.industry Internal medicine medicine Liposomal Irinotecan Hematology business - Language
- ISSN
- 0923-7534